PubMed
Peptide bioregulators: a new class of geroprotectors
Khavinson VK, Morozov VG. Adv Gerontol. 2006
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 2 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 72% said they felt similar to their last entry, 28% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 105 days · Based on 18 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 188 days · Based on 24 repeat reporters
Published sources linked on the Pinealon and TB-500 Fragment wiki pages.
PubMed
Khavinson VK, Morozov VG. Adv Gerontol. 2006
PubMed
Khavinson VK. Biogerontology. 2009
PubMed
Khavinson V, Ribakova Y, Kulebiakin K, et al. Rejuvenation research. 2011
PubMed
Khavinson V, Linkova N, Kozhevnikova E, et al. Molecules (Basel, Switzerland). 2020
PubMed
Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
PubMed
Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026